 ENTYVIOs sales totaled about 130.5 billion in Q2 2021, up 4.1 quarter-on-quarter and 23.5 Q1 2020. Revenue for the companys key 14 medicines increased by 23.9 in the second quarter of 2021 compared to the previous quarter. 